Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)

NCT05254743 is registered in ClinicalTrials.gov with Loxo Oncology, Inc. as lead sponsor.

NCT NCT05254743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05254743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
Lead sponsor
Loxo Oncology, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
July 22, 2022
Completion date
January 31, 2028
Enrollment
737 (estimated)
Sites
143

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, leukemia, b-cell, leukemia, lymphocytic, small lymphocytic lymphoma